Silvercrest Asset Management Group LLC Halozyme Therapeutics, Inc. Transaction History

Silvercrest Asset Management Group LLC

$14.3 Billion
Q3 2024

A detailed history of Silvercrest Asset Management Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 636,589 shares of HALO stock, worth $30.9 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

636,589

Previous 603,631 5.46%

Holding current value

$30.9 Million

Previous $31.6 Million 15.23%

% of portfolio

0.25%

Previous 0.23%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$51.3 - $64.42 $1.69 Million - $2.12 Million	32,958 Added 5.46%	636,589 $36.4 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $22.8 Million - $31.6 Million	-603,631 Reduced 50.0%	603,631 $31.6 Million
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $22.8 Million - $31.7 Million	604,125 Added 100.16%	1,207,262 $63.2 Million
Q1 2024 May 15, 2024	BUY	$33.68 - $41.95 $397,592 - $495,219	11,805 Added 2.0%	603,137 $24.5 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $1.39 Million - $1.76 Million	-41,742 Reduced 6.59%	591,332 $21.9 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $4.26 Million - $5.15 Million	116,904 Added 22.65%	633,074 $24.2 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $5.3 Million - $6.78 Million	174,887 Added 51.24%	516,170 $18.6 Million
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $2.34 Million - $3.97 Million	-71,357 Reduced 17.29%	341,283 $13 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $1.04 Million - $1.54 Million	-25,901 Reduced 5.91%	412,640 $23.5 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $2.11 Million - $2.83 Million	54,687 Added 14.25%	438,541 $17.3 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $3.42 Million - $4.42 Million	91,526 Added 31.31%	383,854 $16.9 Million
Q1 2022 May 16, 2022	BUY	$31.97 - $41.06 $9.07 Million - $11.6 Million	283,570 Added 3237.84%	292,328 $11.7 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $28,001 - $35,860	880 Added 11.17%	8,758 $352,000
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $35,315 - $42,613	918 Added 13.19%	7,878 $320,000
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $5,359 - $7,080	138 Added 2.02%	6,960 $316,000
Q1 2021 May 17, 2021	BUY	$39.51 - $51.45 $8,731 - $11,370	221 Added 3.35%	6,822 $284,000
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $170,371 - $287,935	6,601 New	6,601 $282,000

Others Institutions Holding HALO

# of Institutions

544

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.75B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.

Account

Silvercrest Asset Management Group LLC Halozyme Therapeutics, Inc. Transaction History